ADA updates guideline for pharmacotherapy of T2DM

ADA updates guideline for pharmacotherapy of T2DM

(HealthDay)—In a 2020 American Diabetes Association clinical guideline, published online Sept. 1 in the Annals of Internal Medicine, recommendations are presented for the pharmacologic treatment of adults with type 2 diabetes.

Kacie Doyle-Delgado, D.N.P., from St. Mark's Hospital and St. Mark's Diabetes Center in Salt Lake City, and colleagues updated recommendations relating to the pharmacologic treatment of adults with type 2 diabetes based on a review of the recent evidence.

The authors note that the initial pharmacologic agent preferred for treatment of type 2 diabetes is metformin. In some patients, early combination therapy is recommended at treatment initiation to extend time to treatment failure. In the case of evidence of ongoing catabolism (), if symptoms of hyperglycemia are present, or when hemoglobin A1c or are very high, early introduction of insulin should be considered. To guide the choice of pharmacologic agents, a patient-centered approach should be used. A sodium-glucose cotransporter-2 inhibitor or glucagon-like peptide-1 receptor agonist (GLP-1 RA) with demonstrated cardiovascular disease benefit is recommended for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or indicators of high risk, established kidney disease, or heart failure. GLP-1 RAs are preferred to insulin in patients with type 2 diabetes who need greater glucose lowering than can be obtained with oral agents.

"The medication regimen and medication-taking behavior should be reevaluated at (every three to six months) and adjusted as needed to incorporate specific factors that affect choice of treatment," the authors write.


Explore further

Metformin-based therapy should be first-line treatment for patients with type 2 diabetes at low cardiovascular risk

More information: Abstract/Full Text
Journal information: Annals of Internal Medicine

Copyright © 2020 HealthDay. All rights reserved.

Citation: ADA updates guideline for pharmacotherapy of T2DM (2020, September 1) retrieved 18 September 2020 from https://medicalxpress.com/news/2020-09-ada-guideline-pharmacotherapy-t2dm.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
4 shares

Feedback to editors

User comments